Hepatitis C Therapeutic Registry and Research Network (HCV-TARGET)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2011
  • Initiating Organization: North Carolina Translational and Clinical Science Institute
  • Initiator Type: Academia
  • Disease focus:
    Hepatitis C
  • Location: North America


HCV-TARGET is an international consortium of leading Hepatitis C virus (HCV) investigators who have established a common research database and are conducting a longitudinal observational study to answer important questions about HCV therapy with direct acting antiviral agents.


HCV-TARGET is unique for the following reasons:

Structure & Governance

Led jointly by the University of Florida (UF) and the University of North Carolina (UNC) at Chapel Hill, HCV-TARGET is an international research consortium created to inform the ongoing transformation of HCV treatment and research. As of April 2013, HCV-TARGET includes 103 academic and community sites in 31 states, Puerto Rico, Canada, and Europe. The governance structure includes a Steering Committee, Publication Committee, community advocate, industry advisory council, and regulatory advisory council. UF serves as the Clinical Coordinating Center, and UNC serves as the Data Coordinating Center. HCV-TARGET is conducting an investigator-initiated observational study jointly sponsored by UF and UNC and funded in part by Vertex, Merck, Kadmon, and Genentech through PEGBASE: An Observational Study.


HCV-TARGET is sponsored by Genetech, Kadmon, Merck, Janssen, AbbVie, Gilead Sciences, Bristol-Myers Squibb, and GlaxoSmithKline.


Beginning in April 2013, HCV-TARGET will release interim analyses each spring and fall to provide timely data that can inform clinical practice and improve treatment safety, efficacy, and outcomes. Interim analyses will aim to improve information on populations represented and underrepresented in Phase III clinical trials and to identify and remediate educational gaps and adverse event management. Over time, HCV-TARGET will study long-term morbidity, mortality, and comorbidities associated with treating Hepatitis C and will develop new translational studies and collaborations. A formal publication policy and process has been developed to facilitate analyses of HCV-TARGET data and dissemination of findings.

Sponsors & Partners


Bristol-Myers Squibb



Gliead Sciences




University of Florida

University of North Carolina, Chapel Hill


Last Updated: 04/15/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.